Comparing two treatment approaches for advanced nasopharyngeal cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This phase III clinical trial investigates the effectiveness of concurrent chemoradiotherapy compared to a combination of induction chemotherapy followed by concurrent chemoradiotherapy in patients with locally advanced nasopharyngeal carcinoma. The study aims to determine if the concurrent approach is not inferior to the combined treatment in terms of patient outcomes. Participants will receive either treatment regimen and will be monitored for efficacy and safety. The trial is multi-center, allowing for a diverse patient population.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age 18-65 years old;
2. Pathologically confirmed non-keratinizing nasopharyngeal carcinoma;
3. Stage T3-4N0-1 (according to the UICC/AJCC 8th);
4. No distant metastasis;
5. Have not received anti-cancer treatment in the past;
6. ECOG (Eastern Cooperative Oncology Group of the United States): 0-1;
7. Adequate hematologic, hepatic and renal function.

Exclusion Criteria:

1. The purpose of treatment is palliative;
2. Diagnosed with other malignant tumors at the same time;
3. Malignant tumor history;
4. Pregnancy or breastfeeding, or expect to become pregnant during the clinical trial period;
5. Combined serious illness.

Where it's running

• The First Affiliated Hospital of Sun Yat-sen University
  Guangzhou, Guangdong, China Recruiting

Study contacts

• Study coordinator: Shuang Wu, PHD
• Email: wush77@mail.sysu.edu.cn
• Phone: +862087755766

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Serplulimab with Induction Chemotherapy and Radiotherapy in Locally Advanced Nasopharyngeal Carcinoma

  This phase 3 trial tests whether giving serplulimab with induction chemotherapy and radiotherapy, then maintenance therapy, can help people with locally advanced nasopharyngeal cancer who respond well to initial chemotherapy.

  Recruiting Phase 3 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, Hubei · NCT07177443

• Iparomlimab/Tuvorlimab (QL1706) plus modified TPF induction for locally advanced nasopharyngeal carcinoma

  This trial will test whether adding the dual-antibody Iparomlimab/Tuvorlimab (QL‑1706) to a modified TPF chemotherapy regimen as induction therapy helps adults with newly diagnosed, locally advanced nasopharyngeal carcinoma.

  Recruiting Phase 2 The First Affiliated Hospital of Xiamen University · Xiamen, Fujian · NCT07085234

• Using immunonutrition to reduce oral mucositis in nasopharyngeal carcinoma patients after treatment

  This study is testing if a special type of nutrition can help reduce painful mouth sores in patients with nasopharyngeal cancer who are getting treatment.

  Recruiting at 20 sites First Affiliated Hospital of Guangxi Medical University · Fuzhou, Fujian and 19 other locations · NCT05892354

• Comparing two versus three cycles of chemotherapy for advanced nasopharyngeal cancer

  This study is testing whether two cycles of chemotherapy before radiation is just as effective as three cycles for people with advanced nasopharyngeal cancer.

  Recruiting Phase 3 First Affiliated Hospital, Sun Yat-Sen University · Guangzhou, Other (Non U.s.) · NCT05860868

• Combining Envafolimab with Chemoradiotherapy for Advanced Nasopharyngeal Cancer

  This study is testing if combining a new drug called Envafolimab with standard chemotherapy and radiation can help people with advanced nasopharyngeal cancer live longer without their cancer getting worse.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT05397769

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.